Legend Biotech achieved profitability in the third quarter of 2026, driven by a sharp increase in commercial revenue and disciplined expense management. Total revenue reached $359.5 million, significantly exceeding the consensus estimate of $302.5 million. The company turned a profit with net income of $51.7 million, or $0.13 per share, compared to a net loss of $39.6 million in the same period last year. Results were primarily bolstered by the continued commercial ramp-up of Carvykti following its expansion into earlier lines of therapy.

Key Highlights

  • Carvykti global net trade sales reached approximately $710 million, reflecting a 36% year-over-year increase driven by strong adoption in the second-line setting.
  • Total collaboration revenue reached $353.2 million, as international (ex-U.S.) sales growth surged 86% compared to the prior-year quarter.
  • Operating income improved by $90.1 million year-over-year to $46.8 million, benefiting from higher gross margins and an $18 million reduction in R&D expenses as major clinical trial dosing phases concluded.